Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Practice Guideline
. 2020 Sep;18(9):2138-2144.
doi: 10.1111/jth.15004.

ISTH DIC subcommittee communication on anticoagulation in COVID-19

Jecko Thachil  1 , Nicole P Juffermans  2   3 , Marco Ranucci  4 , Jean M Connors  5 , Theodore E Warkentin  6   7 , Thomas L Ortel  8 , Marcel Levi  9 , Toshiaki Iba  10 , Jerrold H Levy  11
Affiliations
Practice Guideline

ISTH DIC subcommittee communication on anticoagulation in COVID-19

Jecko Thachil et al. J Thromb Haemost. 2020 Sep.

Abstract

Hypercoagulability is an increasingly recognized complication of SARS-CoV-2 infection. As such, anticoagulation has become part and parcel of comprehensive COVID-19 management. However, several uncertainties exist in this area, including the appropriate type and dose of heparin. In addition, special patient populations, including those with high body mass index and renal impairment, require special consideration. Although the current evidence is still insufficient, we provide a pragmatic approach to anticoagulation in COVID-19, but stress the need for further trials in this area.

Keywords: Covid‐19; D‐dimer; anticoagulant; coagulopathy; prothrombin time.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Suggested algorithm for anticoagulation in patients with COVID‐19
See this image and copyright information in PMC

References

    1. Cui S., Chen S., Li X., Liu S., Wang F. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. J Thromb Haemost. 2020;18(6):1421–1424. - PMC - PubMed
    1. Klok F.A., Kruipb M.J.H.A., van der Meerc N.J.M., et al. Incidence of thrombotic complications in critically ill ICU patients with COVID‐19. Thromb Res. 2020;S0049‐3848(20):30120–30121. - PMC - PubMed
    1. Tang N., Bai H., Chen X., Gong J., Li D., Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. 2020;18(5):1094–1099. - PMC - PubMed
    1. Thachil J., Tang N., Gando S., et al. ISTH interim guidance on recognition and management of coagulopathy in COVID‐19. J Thromb Haemost. 2020;18(5):1023–1026. - PMC - PubMed
    1. Hirsh J., Warkentin T.E., Shaughnessy S.G., et al. Heparin and low‐molecular weight heparin: mechanism of action, pharmacokinetics, dosing, monitoring, efficacy and safety. Chest. 2001;119(1Suppl):64S–95S. - PubMed

Publication types

MeSH terms